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Abstract
Osteopontin (OPN) is associated with many diseases, and its role in tumor growth and metastasis has been stud-
ied in breast cancers. Previous studies have described anti-OPN antibodies that could inhibit tumor cell adhesion
and invasion in vitro, but until now, there are no systematic studies on antitumor effects of anti-OPN antibodies
in vivo. In the present study, we have raised several anti-OPN single-chain variable fragments from phage antibody
library and expressed them as single-chain variable fragment–constant region fragment fusion proteins in Chinese
hamster ovary cells. Of them, two antibodies (1A12 and 2H8) were able to inhibit MDA-MB-435s breast cancer cell
attachment, invasion, migration, and colony formation in soft agar. Furthermore, 1A12 and 2H8 inhibited the anti-
apoptotic and prosurvival functions of OPN in human umbilical vein endothelial cell. In human umbilical vein endo-
thelial cell capillary tube formation, chicken chorioallantoic membrane assay, and rabbit corneal micropocket assay,
the two antibodies showed markedly inhibitory effects toward angiogenesis. We investigated antitumor effects of
anti-OPN antibodies in nude mice by assessing xenograft tumor growth and lung metastasis potential. The results
showed that the two antibodies were capable of delaying primary tumor growth and reducing spontaneous lung
metastasis. Epitope mappings of these two anti-OPN antibodies were performed, and a new binding site of 1A12
was revealed. In summary, the present study has demonstrated the roles of anti-OPN antibodies in blocking the
function of OPN, suggesting that they may have the potential to be developed for future clinical use.
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Introduction
Tumor metastasis and angiogenesis are crucial steps in tumor develop-
ment and dissemination. Several growth factors and cytokines play im-
portant roles in the adhesion, migration, invasion, and proliferation of
tumor cells. Among them, osteopontin (OPN) has been linked with
the regulation of metastatic spread of tumor cells by substantial data
and associated with the metastatic phenotype of breast cancer [1].
Osteopontin is a secreted phosphorylated glycoprotein that has di-
verse physiological and pathological functions [2]. Its expression is as-
sociated with a variety of diseases or reactive states, including cancer,
immune diseases, and vascular remodeling. The pivotal role of OPN
in tumor metastasis has been highlighted by many researches [3,4]. In-
creased OPN expression is associated with tumor invasion, progression,
and metastasis of breast, lung, prostate, and colon cancers. Studies have
established a correlation between high levels of OPN protein expres-
sion and malignant invasion by demonstrating OPN expression within
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tumor cells and in the surrounding stroma of numerous human cancers.
Osteopontin is thought to exert its prometastatic effects by interact-
ing with integrins and CD44 receptors. Because of its potential role
in cancer cell motility, growth, and metastasis, OPN could be regarded
as a candidate target in developing diagnostics and therapy for cancer.
It has been shown that OPN affects the behavior of breast cancer
cells in a number of ways by influencing pathways involved in the
control of cell adhesion, migration, and invasion. Incubation with
mammary epithelial cells with OPN (native or recombinant) sup-
ports cell adhesion and induces cell migration and invasion [5].
Not only does OPN affect mammary epithelial cell migration but
it also induces cell invasion through basement membrane Matrigel,
when either added to the cells or endogenously increased by transfec-
tion. The degree of OPN-induced cell migration response may depend
on the type of integrin receptors the cells express. The cells expressing
αvβ3 integrin migrate better in response to OPN than those express-
ing only αvβ5 and β1. MDA-MB-435s breast cancer cells express αvβ3
integrin, whereas some less malignant cell lines (MDA-MB-231,
MCF-7, etc.) do not [6].
Osteopontin was regarded to be an important angiogenic factor in
many processes [7]. Increased vascularity enhances the growth of pri-
mary tumors and provides a poor prognosis of tumor patients. It is
known that both OPN and αvβ3 are expressed by endothelial cells
during vascular remodeling [8]. In vitro, OPN has been found to
promote endothelial cell survival [9] and to induce vascular endothe-
lial growth factor (VEGF) expression by endothelial cells [10], and
OPN might stimulate endothelial cell migration in cooperation with
VEGF [11]. Furthermore, OPNmight contribute to tumor growth and
metastasis by inhibiting apoptosis of endothelial cells. Soluble OPN
inhibits apoptosis of human umbilical vein endothelial cell (HUVEC)
deprived of serum and growth factors and inhibits DNA fragmentation
[12]. Osteopontin also supported tumor cell survival [13].
The production of OPN can contribute to the metastasis pheno-
type through autocrine and paracrine effects. Autocrine effects can
modulate cell proliferation and survival, transforming benign tumor
cells to malignant tumor cells [14]. Conversely, paracrine function of
OPN can provide protection from cytotoxic macrophages by inhibit-
ing the production of nitric oxide [15]. These functions may explain
why tumor cells not expressing OPN are eliminated and provide the
reason for tumor cell escape.
Osteopontin knockout mice showed impaired colony formation in
soft agar and slower tumor growth in vivo compared with tumors in
wild-type mice [16]. Several approaches including silencing of OPN
expression at the messenger RNA (mRNA) and protein levels have
been attempted. Silencing of OPN expression by small interfering
RNA technology resulted in suppression of both in vitro and in vivo
CT26 murine colon adenocarcinoma metastasis [17]. With the in-
creasing interest in OPN as a potentially therapeutic target in different
malignancies, we constructed human OPN-immunized phage anti-
body library to generate anti-OPN antibodies and to study their func-
tions. We investigated the antitumor effects of anti-OPN antibodies
in vitro and in vivo. Our findings indicate that anti-OPN antibodies in-
hibit MDA-MB-435s cell attachment, invasion, migration, and colony
formation in soft agar. The antibodies inhibit angiogenesis and anti-
apoptotic functions of OPN. In vivo xenograft models of MDA-
MB-435s breast cancer have shown that anti-OPN antibodies have
antitumor effects in vivo. These results demonstrate that anti-OPNanti-
bodies may possess therapeutic activity for the treatment of tumors that
are dependent on OPN signaling for growth and metastasis.
Materials and Methods
Animals, Cell Lines, and Proteins
Female athymic nude mice, 4 to 6 weeks old, were obtained from
the Animal Center, Chinese Academy of Sciences. MDA-MB-435s
cells were obtained from the Cell Library of the Institute of Cellular
Biology, Chinese Academy of Sciences. The HUVECs were purchased
from Cascade Biologics (Portland, OR) and grown in the Medium 200
supplemented with low serum growth supplement (Cascade Biologics).
Recombinant humanOPNprotein was cloned fromMDA-MB-435s
cells and expressed in yeast vector pPICZαA and purified.
Generation of Anti-OPN Single-Chain Variable
Fragment–Constant Region Fragment Fusion Proteins
Balb/c mice were immunized with recombinant human OPN and
anti-OPN phage antibody library was constructed using pCAN-
TAB5E phagemid vector (Amersham, Uppsala, Sweden). Biopanning
was performed against the library, and positive clones were determined
by monoclonal phage ELISA.
Single-chain variable fragment–constant region fragment (scFv-Fc)
constructs were generated by cloning scFv into the pcDNA3.1(+) ex-
pression vector that contained the complementary DNA encoding
the hinge-CH2-CH3 regions of the human immunoglobulin G1
heavy chain constant region (Fc). The scFv-Fc plasmids were stably
transfected into Chinese hamster ovary cells. Supernatants were puri-
fied by Protein A chromatography and analyzed by Western blot
analysis and competitive ELISA.
Cell Attachment Assay
The 96-well microtiter plates were coated with OPN, followed by
treatment with 1% BSA for 1 hour at 37°C. To each well, 5 × 104
MDA-MB-435s cells were added in the presence or absence of various
concentrations of anti-OPN antibodies. After incubation for 2 hours at
37°C, the medium was removed and washed twice with PBS gently.
The adherent cells were fixed in 1% methanol, stained with 0.5% crys-
tal violet, and lysed with 2% Triton X-100. The absorbance was mea-
sured at OD595nm.
Cell Invasion Assay through Matrigel
Cell invasion was measured by 24-well Transwell system with poly-
carbonate filters of 8-μm pore size. The upper side was coated with
Matrigel. After rehydration, 5 × 105MDA-MB-435s cells with or with-
out anti-OPN antibodies were added to the top chamber. To the lower
chamber, 600-μl medium containing OPN was added. After 24 hours
of incubation, the cells attached to the lower surface were stained and
counted. Four high-power fields were counted for each well.
Scratch Wound Healing Assay
Monolayers of MDA-MB-435s cells were cultured to near conflu-
ence (>90%) in 12-well plates in triplicate. Streaks were made on the
monolayer culture with 10-μl pipette tips. Experiment was per-
formed with and without anti-OPN antibodies. The cell migrations
were monitored for 24 hours. The migration of cells was determined
by the number of cells that crossed into the wounded area from their
reference point at time zero.
Colony Formation on Soft Agar
The 24-well plates were coated with 0.5 ml of 0.5% agar solution.
MDA-MB-435s cells were suspended in 0.3% agar solution and plated
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on top of the preset agar base and allowed to set. Every other day, 0.2 ml
of medium with or without anti-OPN antibodies was refed to each
well. After 10 days, photographs were taken. The colony formation
ability was evaluated by counting the size of colonies containing more
than 10 cells.
Human Umbilical Vein Endothelial Cell Proliferation Assay
The HUVECs were seeded at 2 × 104 cells per well in 96-well
plates and allowed to adhere overnight before experimentation. They
were serum-starved, and OPN with or without anti-OPN antibodies
were added for 24 hours. Then 1-μCi per well 3H-thymidine was
added and incubated for an additional 6 hours at 37°C. Cells were
washed, fixed with 10% trichloroacetic acid, and counted. All assays
were performed in triplicates and repeated three times.
Human Umbilical Vein Endothelial Cell Apoptosis Assay
Apoptosis was induced in HUVECs by serum deprivation as pre-
viously described [12]. The apoptosis of HUVEC was demonstrated
by nuclear fragmentation of 4′-6-diamidino-2-phenylindole (DAPI)–
stained cells. To determine the apoptosis of HUVEC by FACScan
analysis, HUVECs were seeded at a density of 2 × 105 cells per well
in 6-well plates, and cultured in complete medium for 24 hours. The
cells were then incubated for 24 hours of different treatments. The
cells were stained with fluorescein isothiocyanate (FITC)–conjugated
annexin V/propidium iodide (PI) and analyzed by flow cytometry.
The extent of the apoptosis was quantified as a percentage of annexin
V–positive cells.
Western Blot Analysis
Total protein was isolated from HUVECs receiving different treat-
ments. SDS-PAGE (12%) gels were run and subsequently transferred
to nitrocellulose membranes. The membranes were then blocked in
10% milk in PBS overnight at 4°C. Primary antibodies (Bcl-2, Bax,
and β-actin) were added for 1 hour at room temperature followed by
the appropriate HRP-conjugated secondary antibody at a dilution of
1:2000. Membranes were exposed to chemiluminescence reagents for
1 minute, and bands were detected by exposing to an x-ray film.
Electrophoretic Mobility Shift Assay
The DNA activity of nuclear factor κB (NF-κB) was determined
by electrophoretic mobility shift assay (EMSA). A double-stranded
oligonucleotide containing the DNA-binding site for the NF-κB pro-
teins (forward, 5′ AGTTGAGGGGACTTTCCCAGGC 3′; reverse,
5′ GCCTGGGAAAGTCCCCTCAACT 3′) was end-labeled using
biotin. The HUVECs were treated with OPN with or without anti-
OPN antibodies for 6 hours. Nuclear proteins were extracted with
NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rock-
ford, IL). The nuclear extracts (3 μg) were incubated with 20 fmol
of biotin-labeled double-stranded NF-κB oligonucleotide in binding
buffer. The DNA-binding complex was resolved on a native polyacryl-
amide gel and was analyzed.
Capillary Tube Formation of HUVECs
Capillary tube formation by HUVECs was assayed on Matrigel.
To prepare a gel, 100 μl of Matrigel thawed on ice overnight was
added to each well of a 96-well microtiter plate. After polymerization
of the gel, 2 × 104 HUVECs were plated onto the gel in Medium 200.
In some wells, OPN with or without anti-OPN antibodies were added
to the cells at the time of incubation. The capillary tube formation was
observed under an inverted microscope.
Quantitative Determination of VEGF Expression in HUVEC
The HUVECs were treated with OPN with or without anti-OPN
antibodies for 24 hours. Templates for real-time polymerase chain
reaction (PCR) were obtained by reverse transcription reaction of
total RNA. Primers for VEGF is as follows: forward, 5′-ATC ACG
AAG TGG TGA AGT TC-3′; and reverse, 5′-TGC TGTAGG AAG
CTC ATC TC-3′. Polymerase chain reaction cycling conditions were
95°C for 15 seconds and 60°C for 1 minute for 40 cycles. SYBRGreen
kit (Takara, Shiga, Japan) was used to quantify the PCR products. The
GAPDH gene was used as an endogenous control to normalize for dif-
ferences in the amount of total RNA in each sample.
Chicken Embryo Chorioallantoic Membrane Assay
Gelatin sponge was supplemented with 1) vehicle in PBS alone
(negative control), 2) OPN (200 ng), 3) OPN and anti-OPN antibody
(1μg), or 4) VEGF (200 ng, positive control). The chorioallantoicmem-
brane (CAM) of chicken eggswas added, on day 8,with 1-mm3 sterilized
gelatin sponges. At day 12, CAMwas photographed in ovowith a stereo-
microscope equipped with a digital camera. The angiogenesis response
was evaluated as the number of vessels converging toward the gelatin
sponge [18].
Rabbit Corneal Micropocket Assay
Slow-release pellets were prepared by mixing aliquots of OPN/
sucralfate solution with or without anti-OPN antibodies (1 μg) and
12% Hydron stock solution. New Zealand white rabbits were anesthe-
tized, and topical anesthesia was applied to the corneal surface. A 3-mm
incision was made at the center of the cornea, and a micropocket was
created in the cornea stroma, which extended 1 mm away from the
limbus. The pellets were advanced into the corneal stromal pocket.
The corneas of the rabbits were examined in a masked manner by
a slit lamp microscope at 10× magnification. The vascular response
was measured as the maximal vessel length (VL) extending from the
limbal vasculature toward the pellet and the contiguous circumferen-
tial zone of neovascularization (CN = clock hours of neovasculariza-
tion, where 1 clock hour equals 30° of arc). The area of neovascular
response was calculated using the formula: area (mm2) = 0.2 × π ×
VL (mm) × CN (mm).
In Vivo Xenograft Animal Study
Female athymic mice (∼4–6 weeks) were anesthetized and a small
incision (0.5 mm) was made in the skin over the lateral thorax below
the right limb. The mammary fat pads (MFPs) were exposed, and
MDA-MB-435s cells (5 × 106 in 100 μl of Dulbecco’s modified Eagle’s
medium) were orthotopically injected into the MFP. A minimum of
12 animals was used per group. Among them, six animals were used
to observe primary tumor growth rate and terminated at 12 weeks,
and six were used to determine spontaneous lung metastasis and termi-
nated when primary tumor volume reached 1000 mm3. For antibody
treatment, themice were treated twice per week with anti-OPN scFv-Fc
(5 mg/kg body weight, intraperitoneally), and the control groups
were treated with PBS and control scFv-Fc (7B6, 5 mg/kg body weight,
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intraperitoneally). The treatment duration was 4 weeks. At the end of
the experiment, mice were killed, and primary tumors and lungs were
removed, fixed, and embedded.
Tumor and lung tissue sections were processed by hematoxylin
and eosin staining for primary tumor and metastasis foci. For every
two sections, the lung metastasis foci were counted. The grades of me-
tastasis foci were determined as follows: grade 1, <20 cells/foci; grade 2,
20 < cells < 50/foci; grade 3, 50 < cells < 100 cells/foci; grade 4, >100 cells/
foci. The total number of metastasis foci was counted as grade 1 × 1 +
grade 2 × 2 + grade 3 × 3 + grade 4 × 4.
Anti-CD31 antibody was used to identify capillary-sized vessels in
frozen sections of primary tumors. The tumor sections were incubated
with rat antimouse CD31 overnight at 4°C. After being washed with
PBS, the slides were incubated with goat antirat antibody conjugated
to PE for 1 hour in the dark. The microvessel counting procedures as
described by Weidner [19] was used. The microvessel density (MVD)
was expressed as the number of vessels per square millimeter.
For immunofluorescence double staining of CD31/TUNEL, the
sections were stained with CD31, and washed with PBS. TUNEL
was performed using a commercial kit (Calbiochem, San Diego,
CA). The sections were examined with under an Olympus Inverted
System (Olympus, Tokyo, Japan).
Epitope Mappings
Epitope mappings of anti-OPN antibodies were performed using
Ph.D.-7 Phage Display Peptide Library Kit (New England Biolabs, Inc.,
Ipswich, MA). After three rounds of panning, the phages eluted were
then cloned and amplified for DNA sequencing and immunoanalysis.
Statistical Methods
Data were analyzed using the unpaired t test with 2-tailed P value
or analysis of variance (for multiple comparisons) to calculate the sta-
tistical significance between control and treated groups. The results
were presented as means ± SEM. Statistically significant differences
were defined as having P < .05.
Results
Construction and Biopanning of Antihuman OPN Immunized
Phage Library
Anti-OPN antibody library was constructed from human OPN-
immunized mice (Figure 1A). The antibody library size was deter-
mined after serial dilution of the bacteria plated onto SOBAG plates
(Gibco, Portland, OR), which was 5 × 108 colony-forming units.
Four rounds of biopanning were performed to select specific anti-
OPN antibodies. In total, 120 colonies were randomly picked out
and tested by monoclonal ELISA after biopanning procedures, yield-
ing 21 OPN-specific antibodies. Four unique anti-OPN phage scFvs
were identified (1A12, 2H8, 7B6, and 7H12) by sequence analysis of
the individual clones. The reactivity of anti-OPN antibodies to OPN
is shown in Figure 1B.
The phage scFvs were cloned into the scFv-Fc expression cassette
and expressed in Chinese hamster ovary cells as Fc fusion proteins.
Recombinant scFv-Fc protein was batch-purified by Protein A col-
umn. SDS-PAGE analysis in denatured conditions revealed that
the molecular weight of scFv-Fc was approximately 60 kDa. West-
ern blot analysis confirmed that the purified scFv-Fc fusion protein
specifically reacted with recombinant human OPN as the antigen
(Figure 1C ). To assess the specificity of purified scFv-Fc fusion pro-
teins, competitive ELISA was performed to determine the binding
specificity. As shown in Figure 1D, in the presence of the competitor
(scFv-Fc), the phage scFv tested was partially inhibited from subse-
quent binding to the plated OPN antigen. The inhibition percent of
phage scFv (1011 plaque-forming units/ml) was 40% when 10 μg/ml
of scFv-Fc was added as the competitor.
Anti-OPN Antibodies Inhibited MDA-MB-435s
Cell Attachment, Invasion, Migration, and Colony
Formation in Soft Agar
To investigate the interaction of OPN with MDA-MB-435s cells,
we performed cell attachment assay. As shown in Figure 2A, 1A12 and
2H8 blocked the cell attachment of MDA-MB-435s cells to human
OPN, whereas 7B6 and 7H12 did not block the attachment of
MDA-MB-435s cells on plates coated with 10 μg/ml of OPN. Be-
cause we found that anti-OPN antibody 7B6 did not inhibit cell at-
tachment and invasion, we used 7B6 as the control antibody in the
following experiments.
Matrigel invasion assay was used to determine whether anti-OPN
antibodies had blocking functions toward the invasion. MDA-MB-
435s cells were seeded on Matrigel inserts, and OPN was added in the
lower chamber. After 24 hours of incubation, the cells on the lower
surface of the filters were counted. 1A12 and 2H8 significantly inhib-
ited cell invasion through Matrigel-coated filters compared with 7B6
and 7H12 [32 ± 4 vs 90.7 ± 7 (number of invaded cells ± SD)]. These
results are shown in Figure 2B.
Cells exposed to anti-OPN antibodies were analyzed for their rate
of migration. More cells appeared in the wounded gap, which repre-
sented enhanced healing of the wounded area. The cells crossed the
line during 24 hours was taken as an index of wound healing. As shown
in Figure 2C , the MDA-MB-435s cells treated with 1A12 and 2H8
migrated across an artificial in vitro wound much less efficiently than
the control antibody.
We examined the efficacy of the anti-OPN antibodies in inhibiting
breast cancer cell anchorage–independent growth (soft agar colony for-
mation) in vitro because this activity correlates closely with tumorige-
nicity in vivo [20]. Anti-OPN antibodies significantly altered soft-agar
colony-forming activity. As shown in Figure 2D, the clone sizes of
1A12- and 2H8-treated cells were significantly smaller than those of
the control antibody-treated cells.
Anti-OPN Antibodies Inhibited OPN-Mediated
Antiapoptotic and Prosurvival Functions
We investigated the effect of OPN on proliferation and apoptosis
of HUVEC. The addition of OPN to the serum-deprived HUVECs
reduced the amount of cell death. In the presence of OPN, 3H-
thymidine uptake increased 3.08 ± 0.64-fold in HUVECs (Figure 3A,
P < .01); however, this incorporation uptake decreased 2.76 ± 0.35-
fold when anti-OPN antibodies were added. Our results showed that
OPN may support cell survival under conditions of serum withdrawal,
conditions that have been shown to induce HUVEC apoptosis. In the
presence of anti-OPN antibodies, the prosurvival function of OPN was
inhibited significantly.
Induction of apoptosis was analyzed with the help of DAPI, which
caused a regular staining in intact nuclei, but an irregular staining
in apoptotic cells [21]. As shown in Figure 3B, ∼30% of HUVECs
lost membrane integrity after treatment with serum deprivation for
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24 hours, compared with ∼10% of cells in control cultures treated with
the normal serum culture condition. The HUVECs treated with OPN
showed less DAPI-stained cells compared with nontreated ones. The
addition of anti-OPN antibodies abrogated the function of OPN.
FACScan analysis of annexin V/FITC-PI staining showed that se-
rum deprivation induced apoptosis of HUVECs. Exogenous soluble
OPN protected HUVECs from serum deprivation–induced apoptosis.
Anti-OPN antibodies inhibited OPN-mediated antiapoptotic function
on HUVECs (Figure 3C).
The expressions of apoptosis-related proteins (Bcl-2 and Bax) were
analyzed by Western blot analysis. The HUVECs were deprived of
factors as described above, with or without OPN and anti-OPN anti-
bodies. Proapoptotic Bax expression was upregulated when anti-OPN
antibodies were added compared with OPN alone. Conversely, anti-
apoptotic Bcl-2 expression was downregulated (Figure 3D).
The nuclear extracts were prepared and used for EMSA using biotin-
labeled NF-κB oligonucleotides. The results are shown in Figure 3E .
In OPN-treated HUVECs, the NF-κB pathway was activated, which
provided a protective function to the cells. The DNA-protein com-
plex was specific, as unlabeled NF-κB oligomer inhibited the sig-
nal, whereas unrelated oligomer had no effect. In contrast, cells
pretreated with anti-OPN antibodies did not induce NF-κB activity,
and the control antibody had no effect inhibiting protective function
of OPN.
Anti-OPN Antibodies Interfered with Angiogenesis In Vitro
and In Vivo
The effect of anti-OPN antibodies on capillary tube formation of
the HUVECs on the Matrigel was evaluated. Osteopontin-cultured
Figure 1. The construction and biopanning of phage antibody library. (A) Construction of phage antibody library. Electrophoresis was
performed on 1% agarose gel, and PCR products were visualized by ethidium bromide. The lengths of V H, V L, and scFv were approxi-
mately 350, 325, and 750 bp, respectively. (B) Binding of positive clones to immobilized OPN. After immobilization of OPN on 96-well
microtiter plates, wells were washed and incubated with different phage scFv clones. Unbound phage scFvs were washed away, and
bound phage scFvs were detected by HRP-conjugated anti-M13 antibody. BSA was used as negative control antigen. (C) Western blot
analysis of scFv-Fc. Lane M indicates marker protein; 1A12, 2H8, 7B6, 7H12, different scFv-Fc. The results confirmed that the purified
scFv-Fc fusion protein specifically reacted with recombinant human OPN as the antigen. The band was approximately 60 kDa. (D) Com-
petitive ELISA was performed to determine the competitive binding inhibition between phage scFv and scFv-Fc. Inhibition of phage scFv
binding to OPN was observed by using scFv-Fc fusion protein as a competitor. The bound phages were detected by ELISA with HRP-
conjugated anti-M13 antibody. Comparable data were obtained in three independent experiments.
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HUVECs developed tube formation and complete networks within
12 hours. The HUVECs incubated with OPN plus anti-OPN anti-
bodies did not form complete capillary-like structures. In the presence
of the control antibody (7B6), tube formation was not inhibited. Rep-
resentative pictures are shown in Figure 4A. Tube length per field was
calculated at time point of 4, 6, and 8 hours after treatment. The re-
sults of this in vitro assay indicated that anti-OPNantibodies had poten-
tial antiangiogenic activity.
Quantitative reverse transcription–PCR showed that treatment
with OPN increased the mRNA expression of VEGF compared with
untreated HUVECs. When HUVECs were pretreated with anti-OPN
antibodies and OPN was added, there was not an increase in VEGF
mRNA expression level (Figure 4B).
The effects of anti-OPN antibodies on blood vessel formation
were monitored on the CAM of 8-day-old chicken embryos. As shown
in Figure 4C , OPN induced a strong angiogenic response in the
CAM, similar to that of VEGF. No vascular reaction was detectable
in the embryos treated with PBS. Anti-OPN antibodies showed a
strong and reproducible antiangiogenic effect in the CAM assay.
Few blood vessels penetrated into the region where the anti-OPN anti-
bodies were applied. In contrast, the control antibody did not have
this effect.
To further investigate the function of anti-OPN antibodies on angio-
genic activity in vivo, OPN-induced rabbit corneal neovascularization
was studied. On the seventh postoperative day, the rabbits showed no
signs of discomfort. Slit lamp observation reveled that all eyes were non-
inflammatory, and no edema was observed in any of the eyes. Control
pellets with only PBS did not induce an angiogenic response. Implants
containing VEGF and OPN induced corneal neovascularization. In the
presence of 1A12 and 2H8, angiogenesis toward OPNwas significantly
inhibited. Implants containing OPN plus control antibody still gave
positive response. The vascular areas of anti-OPN antibody groups were
decreased by 60% (P < .01; Figure 4D) compared with control. Repre-
sentative corneas were examined histologically and no neutrophils were
found, indicating that nonspecific inflammation was not a contributing
factor in any of the corneal responses (data not shown). These findings
demonstrated that anti-OPN antibodies had inhibitory function toward
angiogenesis in vivo.
Figure 2. In vitro function of anti-OPN antibodies. (A) Cell attachment of MDA-MB-435s cells was inhibited by anti-OPN antibodies. MDA-
MB-435s cells were plated on wells coated with 10 μg/ml of OPN in plating medium alone or medium containing anti-OPN antibodies.
1A12 and 2H8 inhibited cell attachment to OPN at the concentration of 25 μg/ml. 7B6 and 7H12 did not have this effect. The inhibition
rate of 1A12 and 2H8 (25 μg/ml) was approximately 60%. *P < .05. (B) Anti-OPN antibodies inhibited Transwell invasion of MDA-MB-
435s cells. MDA-MB-435s cells in plating medium alone or in plating medium containing anti-OPN antibodies were seeded on polycar-
bonate filters with OPN in the lower chamber of Transwell system. Cells that invaded through the filter in response to OPN in the lower
chamber were quantified by cell staining. The error bars represent the SD from three independent experiments. 1A12 and 2H8 (25 μg/ml)
significantly inhibited cell invasion, whereas 7B6 and 7H12 did not have an inhibitory effect. *P < .05. (C) Scratch wound healing assay.
MDA-MB-435s cells were grown in monolayer until confluent and were then serum-starved. After being wounded, the monolayers were
treated with anti-OPN antibodies for 24 hours. 1A12 and 2H8 (25 μg/ml) inhibited MDA-MB-435s cell migration. The graph showed the
mean and SD of values from a representative experiment performed in triplicate. The results were similar in repetitions. *P < .05. (D)
Anti-OPN antibodies inhibited MDA-MB-435s colony formation in soft agar. The clone sizes of the anti-OPN antibody group (1A12 and 2H8)
were smaller than the clone sizes of the untreated and control groups. *P < .05.
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Tumor Growth and Spontaneous Lung Metastasis of
MDA-MB-435s Cells in Nude Mice Were Inhibited by
Anti-OPN Antibodies
Because expression of OPN by breast cancer cells contributes to
tumor growth and metastasis, we next determined the effect of anti-
OPN antibodies on breast cancer xenograft model. MDA-MB-435s
cells were xenografted into the MFP of female nude mice to observe
tumor growth and spontaneous lung metastatic ability. Primary tu-
mors became readily apparent approximately 2 weeks after injection
and tumor take was 100%. 1A12 and 2H8 group had a longer la-
tency period, taking approximately 8 weeks to reach a mean tumor
volume of ∼100 mm3 compared with PBS and control antibody group
approximately 4 weeks. Tumors treated by 1A12 were also less vascu-
larized, especially in the periphery where angiogenesis was prominent.
Overall, tumors from the PBS and control antibody groups grew at
a more accelerated rate than those of the 1A12 and 2H8 groups, pro-
ducing significantly larger tumor volumes from week 2 to 12 (P <
.01; Figure 5A).
The lung metastasis foci were examined under a microscope. Rep-
resentative histological sections of spontaneous lung metastases are
shown in Figure 5B. The incidence of spontaneous lung metasta-
sis was significantly higher in PBS and control groups. Whereas
only 16.7% (1 of 6 from the 1A12- and 2H8-treated groups) of mice
had metastasis foci in the lungs, 83.3% (5 of 6) of the mice in the
PBS and control groups had multiple metastasis foci in the lungs.
The metastasis foci were observed on the lung surface and as clus-
ters in interior regions. In the PBS-treated mice, the metastasis foci
contained much larger, densely packed tumor masses, sometimes
the tumor masses merged to bigger clusters, whereas the anti-OPN
antibody-treated mice had much smaller metastasis foci. We also
compared the different grades of lung metastasis foci. The grades
of metastasis foci were mainly grades 2 to 3. These results show that,
in this spontaneous metastasis model, anti-OPN antibodies were
highly effective in reducing lung metastasis.
We determined whether blockade of OPN by antibodies could
result in the suppression of tumor angiogenesis. Tumor-associated
Figure 3. Effect of anti-OPN antibodies on serumdeprivation–induced apoptosis inHUVECs. (A) 3H-thymidine incorporation uptake inHUVECs.
The HUVECs were maintained in Medium 200 supplemented with low serum growth supplement and were incubated for 24 hours. Then the
cells were extensively washed with PBS, and the medium was changed to serum-free Medium 200 containing OPN with or without anti-OPN
antibodies and incubated for 24 hours. Cell proliferation was assayed 24 hours after serum deprivation. 3H-thymidine incorporation uptake
was examined to present DNA synthesis. Data were expressed as mean ± SD of three experiments. *P< .05. (B) DAPI staining of apoptotic
cells. Nuclear morphology was examined by DAPI staining as described in theMaterials andMethods section. Note the nuclear condensation
and fragmentation in the serumdeprivation group,whichwas indicative of apoptosis. (C) The apoptosis of HUVECswas determined by annexin
V/PI staining and FACScan analysis. The percentage of cells found in each quadrant of the dot plot is depicted. Results are shown as represen-
tative of three independent experiments. Placement of HUVEC in theminimal medium for 24 hours significantly induced apoptosis when com-
pared with the untreated cells. Treatment of HUVEC in the minimal medium with OPN resulted in a significant decrease in the number of
apoptotic cells. Data shown were the means of three separate experiments ± SD (P < .01, 1% BSA vs untreated). Anti-OPN antibodies
1A12 and 2H8 abrogated the antiapoptotic function of OPN. (D) Bcl-2 family proteins were analyzed by Western blot analysis. The HUVECs
were cultured in the presence or absence of OPN (with or without anti-OPN antibodies) for 24 hours. After cultivation, we assessed the expres-
sion of Bcl-2 and Bax in HUVECs using Western blot analysis as described in the text. (E) Electrophoretic mobility shift assay was performed
to determine the NF-κB activity of OPN- and anti-OPN antibody–treated HUVECs. Compared with untreated HUVECs, OPN treatment activated
NF-κB activity, and anti-OPN antibody treatment abrogated this function.
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neovascularization as indicated by MVDwas examined by immunohisto-
chemistry using anti-CD31 antibody. As shown in Figure 5C , we found a
significant reduction in tumorMVD/field after treatment with anti-OPN
antibodies compared with those of PBS and control antibody groups.
These results suggest that the inhibition of tumor growth by anti-OPN
antibodies is partly caused by the suppression of tumor angiogenesis.
We also determined whether anti-OPN antibodies inhibited the
function or induced apoptosis of tumor endothelial cells. CD31
(red )/TUNEL (green) double labeling revealed that endothelial cells
were only in the tumors of mice treated with anti-OPN antibodies.
Apoptotic endothelial cells were not identified in the tumor of PBS-
or control-treated mice (Figure 5D).
Mapping of Epitopes
Sequence analysis of peptides reactive to anti-OPN antibodies
showed that the epitope of 1A12 was located within the C-terminal
amino acids of human OPN (Asn-Ala-Pro-Ser-Ser-Asp, amino acids
212-216), and the epitope of 2H8 was targeted to a classic epitope
Gly-Arg-Gly-Asp-Ser, as shown in Table 1. The epitope of 7B6 was
located within the exon 4 of human OPN. Researches have shown
that the OPN molecule contains multiple binding sites in addition
to the classic arginine-glycine–aspartic acid sequence. These epitopes
of the OPN molecule interact with different cellular receptors and
modulate distinct cellular functions [22]. The different epitopes of
the anti-OPN antibodies might help explain the different functions
of the antibodies.
Discussion
Osteopontin plays an important role in the steps toward cancer cell
metastasis, including binding to cell receptors and communicating the
signals that determine cell proliferation, migration, and invasion.
Figure 4. Antiangiogenesis effect of anti-OPN antibodies. (A) Inhibitory effect of anti-OPN antibodies on in vitro HUVEC capillary tube
formation. The HUVECs were plated on Matrigel (100 μl per well) at a density of 1 × 104 cells per well and treated with OPN in the
absence and presence of anti-OPN antibodies. The ability to form tubes was inhibited in the presence of anti-OPN antibodies. The
experiment was repeated three times, and representative pictures are shown. *P < .05. (B) Quantitative real-time PCR determination
of VEGF mRNA expression. Vascular endothelial growth factor mRNA expression was determined after treatment of HUVEC with OPN
with or without anti-OPN antibodies. There was an increase in VEGF mRNA expression treated with OPN compared with that of un-
treated group. When anti-OPN antibodies were added together with OPN, this increase was not observed. *P< .05. (C) Chicken embryo
CAM assay. Osteopontin was angiogenic in the chicken embryo CAM assay. On day 8, gelatin sponges loaded with OPN (200 ng), VEGF
(200 ng), or PBS was applied to the chicken CAM, and its effect on vascular development was evaluated. In some experiments, 1 μg of
1A12 and 2H8 was added simultaneously with OPN to examine its ability to inhibit the OPN-induced angiogenic response. Neovascu-
larization was observed in OPN and VEGF group, whereas no vascular response was observed in control CAM with PBS. In the presence
of 1A12 and 2H8, the angiogenesis responses were significantly reduced. Experiments were repeated three times, with a minimum of
eight embryos in each treatment group. *P < .05. (D) Anti-OPN antibodies inhibited angiogenesis mediated by OPN in the rabbit corneal
micropocket assay. Representative slit lamp photographs of rabbit corneas on day 7 after implantation with Hydron/sucralfate pellets
containing 1) OPN alone (200 ng), 2) OPN and anti-OPN antibodies, 3) OPN and control (7B6), 4) PBS, and 5) VEGF (200 ng). The results
showed that OPN alone induced a neovascular response from the limbal vessels and reached toward the pellet. Anti-OPN antibodies
inhibited the neovascular response when added together with OPN. No response was observed when PBS pellet was implanted. *P< .05.
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Transformed cells are often characterized by the abundant secretion of
OPN [23], including breast cancer, prostate cancer, osteosarcoma, and
squamous cell carcinoma. Breast cancer cells themselves are capable of
secreting OPN, which shows promise as a prognostic marker in breast
cancer patients [24]. MDA-MB-435s cell line, which expresses and
secretes OPN, is known to be tumorigenic and highly metastatic,
and it was used in the xenograft tumor model in our study.
To inhibit the function of OPN, we used phage antibody display
technology and successfully generated a panel of OPN-specific scFvs
using phage antibody library. After sequence analysis, we chose four
of them to study their function in vitro and in vivo. The fusion to Fc
fragment gave scFv prolonged serum half-life and provided a simple
route for purification through Protein A affinity chromatography.
Detachment and migration from the primary tumor and invasion
of surrounding blood or lymphatic vessels are critical and complex
steps in clinically metastatic diseases. We used scratch wound healing
assay to determine the efficacy of anti-OPN antibodies in inhibit-
ing tumor cell migration. Matrigel invasion assay was used to de-
termine the ability of tumor cells to cross the basement membrane.
In in vitro studies of cell attachment, migration, and invasion, anti-
OPN antibodies 1A12 and 2H8 successfully inhibited these func-
tions, which simulated the in vivo conditions of animals. The capacity
of cells to grow in semisolid medium is supposed to reflect the cells’
independence of contact with a physiologically relevant extracellu-
lar matrix. When anti-OPN antibodies 1A12 and 2H8 were added
in the soft agar, the anchorage-independent growth was significantly
inhibited. We proposed that the antibodies might neutralize the
OPN secreted by the tumor cells and interrupt the ligation of OPN
to its receptors.
We investigated the ability of OPN to protect HUVECs against
serum deprivation–induced apoptosis, and this function can be sig-
nificantly inhibited by the pretreatment of anti-OPN antibodies.
Figure 5. In vivo study of anti-OPN antibodies. (A) Efficacy of anti-OPN antibodies on the primary tumor volume of MDA-MB-435s cells
orthotopic xenografts in nude mice. Animals were divided into four experimental groups receiving different treatments. Anti-OPN anti-
bodies (1A12, 2H8, and 7B6) or PBS was administrated at 5-mg/kg body weight twice per week beginning at the time of tumor cell
implantation in the MFP. The experiment was terminated after 12 weeks of initial inoculation. The tumors were measured twice per
week with calipers, and tumor volumes were calculated. (B) Lung metastasis of breast cancer xenograft model. Female nude mice were
given injections of 5 × 106 MDA-MB-435s cells into the MFP. Representative lung tissue sections of hematoxylin and eosin staining from
the nude mice after MFP injection of MDA-MB-435s cells with or without anti-OPN antibody treatment. Arrows indicate tumor metastasis
sites. Anti-OPN antibodies treatment inhibited lung metastasis in the orthotopic model. The metastasis foci and grade decreased com-
pared with those of the PBS and control groups. *P< .05. (C) Angiogenesis in tumor tissue sections after immunofluorescence staining of
blood vessels with anti-CD31 antibody and MVD counting. Representative microscopic fields from the tumors showed a higher density of
blood vessels in the PBS or control group than in the anti-OPN antibody groups. CD31-positive microvessels were stained in red and nuclei
were stained by Hoechst 33258 in blue. Blood vessels in tumor sections stained with anti-CD31 were counted from five microscopic fields
for all tumors from the six mice in each treatment group are shown. Results are themean± SD of six animals per group. *P< .05. (D) CD31/
TUNEL double staining showed that no apoptotic endothelial cells appeared in the PBS or the control group, whereas in the tumors from
anti-OPN antibodies groups, endothelial cells that underwent apoptosis were identified.
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DAPI staining of nuclear morphology of HUVEC confirmed serum
deprivation in the induction of apoptosis. By 3H-thymidine incorpo-
ration assay, we demonstrated that OPN was able to protect the sur-
vival of HUVECs under apoptotic condition. When anti-OPN
antibodies–pretreated HUVECs were added with exogenous OPN,
the cells could not be protected by OPN. FACScan analysis of annexin
V/FITC-PI staining of apoptotic cells demonstrated the antiapoptotic
function of OPN, and 1A12 and 2H8 inhibited the function of OPN.
Western blot analysis showed that the antiapoptosis protein Bcl-2 was
upregulated when treated with OPN, and compared with untreated
HUVEC, the proapoptotic protein Bax was downregulated when
treated with OPN. When anti-OPN antibodies were added, the func-
tions of OPN were abrogated. The results of EMSA suggested that
NF-κB was activated when OPN was added, and anti-OPN antibodies
inactivated the function. These results were consistent with previous
reports of antiapoptotic and prosurvival functions of OPN [12]. Endo-
thelial cell and tumor cell interacted with each other to facilitate the
invasion andmigration of tumor cells [25]. Therefore, the antiapoptotic
function of OPN might help to explain the metastasis ability of tumor
cells that express OPN. Treatment with anti-OPN antibodies inhibited
the antiapoptotic function ofOPNand thus could help to inhibit tumor
cell metastasis from blood vessel.
Angiogenesis plays a key role in many physiological processes and
pathological processes such as the development and progression of
tumors [26]. Tumor-associated neovascularization is necessary for
the development and metastasis of solid tumors [27]. OPN is one of
the genes differentially expressed during in vitro angiogenesis [28], and
its expression has been correlated to VEGF expression [11,29], one of
the most potent stimulator of angiogenesis. We studied anti-OPN
antibodies in inhibiting angiogenesis in vitro and in vivo. The HUVEC
capillary tube formation is a multistep process involving cell adhesion,
migration, differentiation, and growth. Blockage of the function of
OPN by anti-OPN antibodies interrupted the capillary tube formation
process. Next, we determined the function of anti-OPN antibodies in
in vivo models of angiogenesis. In agreement with the in vitro findings,
OPN caused newly formed blood vessels of the chick embryo CAM.
In the presence of the anti-OPN antibodies 1A12 and 2H8, this angio-
genic effect of OPN was significantly inhibited. Rabbit corneal micro-
pocket assay indicated that anti-OPN antibodies specifically suppressed
OPN-induced corneal neovascularization in vivo. We performed the
two in vivo angiogenesis assays to demonstrate that OPN may initiate
the formation of new blood vessels, an event essential for tumor pro-
gression, and anti-OPN antibodies effectively inhibited the function of
OPN in angiogenesis.
The metastatic disease requires that tumor cells complete all steps of
a complex process. The formation of a secondary tumor colony in a
distant organ is the culmination of a series of sequential and highly
selective events [30]. We observed in a highly aggressive MDA-MB-
435s xenograft animal model that primary tumor growth and sponta-
neous lung metastasis rate were significantly decreased in the presence
of the anti-OPN antibodies 1A12 and 2H8, suggesting that these anti-
bodies had inhibitory functions toward the function of OPN in vivo.
Microvessel density in anti-OPN antibodies–treated tumors decreased
significantly compared with those of the PBS or the control group,
indicating that anti-OPN antibodies can block the angiogenic function
of OPN in vivo. Reduced angiogenesis and increased endothelial cell
apoptosis in these tumors are presumably contributing to the inhibi-
tion of tumor growth and spontaneous lung metastasis.
One of the major mechanisms by which OPN influences cell be-
havior is through interactions with various integrins, including αvβ3,
α9β1, αvβ5, and α5β1. Osteopontin has multiple domains, and
multiple forms of human OPN are generated by alternative splicing.
Osteopontin has the arginine-glycine–aspartic acid domain for bind-
ing with integrins [31,32]. It also has a heparin-binding domain close
to the carboxyl-terminus of the OPN protein involved in the binding
to different isoforms of CD44 [33]. Furthermore, OPN contains the
binding domain for calcium ions close to the carboxyl-terminus of
OPN, and binding to calcium has been indicated to regulate inter-
actions with integrin-binding domains [31]. Recent progress has de-
fined that splice variant OPN-c is a highly specific marker for
transformed cells [34]. In our study, the epitopes of 7B6 were
mapped to the exon 4 of full-length human OPN (OPN-a), which
is absent in the splice variant OPN-c. Because OPN-c strongly sup-
ported anchorage-independent growth, we deduce that only targeting
OPN-a, but not OPN-c, was not sufficient to block the function of
this diverse protein. We have found a new possible functional epitope
near the calcium-binding loop of OPN, although the detailed func-
tion of the epitope still needs to be further investigated. A better under-
standing of the function/structure relationships will help clarify the
different epitopes of OPN in various diseases.
In summary, the present study has provided four OPN-specific
antibodies, and two of them are shown to possess inhibitory effects
toward the functions of OPN in vitro and in vivo. On the basis of
these observations, we speculate that these two anti-OPN antibodies
have the potential for future therapeutic use.
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